FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable or Metastatic Cholangiocarcinoma By Ogkologos - May 20, 2026 80 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for safety and efficacy is based on the findings from the eNRGy study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Lo que deben saber las personas con cáncer de mama y... January 4, 2024 Reunión anual de la American Society of Clinical Oncology de 2023:... May 25, 2023 Researchers Discover Genetic Marker That Increases Risk Of Premenopausal Breast Cancer August 2, 2019 ESMO Announces Results of 2025 Elections June 14, 2025 Load more HOT NEWS Immunotherapy after Surgery Shows Long-Term Benefits for High-Risk Bladder Cancer Tackling under-representation of Black data scientists in cancer research Noninferiority of OS with 3 Months Compared to 6 Months of... EMA Recommends Granting a Marketing Authorisation for Lisocabtagene Maraleucel
